CLINICAL EFFICACY OF COMBINED LIPID-LOWERING THERAPY IN ISCHEMIC HEART DISEASE: OUTCOMES OF STATIN AND EZETIMIBE THERAPY

Authors

  • Qobilov Dostonbek Rustamovich, Maksudova Malika Khamdamjanovna, Jabborov Ozimboy Otakhonovich Tashkent State Medical University image/svg+xml Author

Keywords:

ischemic heart disease, coronary artery disease, statins, ezetimibe, LDL cholesterol, lipid-lowering therapy, combination therapy, cardiovascular events, myocardial infarction, secondary prevention.

Abstract

Ischemic heart disease (IHD) is one of the most important manifestations of atherosclerotic cardiovascular disease and remains a major cause of recurrent myocardial infarction, coronary revascularization, heart failure, and cardiovascular mortality. Low-density lipoprotein cholesterol (LDL-C) is a causal factor in the development and progression of atherosclerosis, making intensive LDL-C reduction a cornerstone of secondary cardiovascular prevention. Although statins remain the first-line pharmacological treatment, a substantial proportion of patients do not achieve recommended LDL-C targets with maximally tolerated statin therapy alone. The addition of ezetimibe provides a complementary mechanism of LDL-C reduction by inhibiting intestinal cholesterol absorption. This literature review evaluates the clinical efficacy of combined statin and ezetimibe therapy in patients with IHD. Evidence from randomized controlled trials, comparative studies, and contemporary clinical guidelines was analyzed. The IMPROVE-IT trial demonstrated that adding ezetimibe to statin therapy after acute coronary syndrome produced additional LDL-C reduction and a significant decrease in major cardiovascular events [1]. The RACING trial subsequently showed that moderate-intensity rosuvastatin combined with ezetimibe was non-inferior to high-intensity rosuvastatin monotherapy for a composite cardiovascular outcome, while achieving higher rates of LDL-C target attainment [2]. Current evidence therefore supports combination therapy as an effective strategy for patients who do not achieve LDL-C targets with statin monotherapy or who require intensive lipid lowering while minimizing statin-related intolerance.

References

1.Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes // New England Journal of Medicine. — 2015. — Vol. 372, No. 25. — P. 2387–2397. — DOI: 10.1056/NEJMoa1410489.

2.Kim B.K., Hong S.J., Lee Y.J., et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial // The Lancet. — 2022. — Vol. 400, No. 10349. — P. 380–390. — DOI: 10.1016/S0140-6736(22)00916-3.

3.Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel // European Heart Journal. — 2017. — Vol. 38, No. 32. — P. 2459–2472. — DOI: 10.1093/eurheartj/ehx144.

4.Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk // European Heart Journal. — 2020. — Vol. 41, No. 1. — P. 111–188. — DOI: 10.1093/eurheartj/ehz455.

5.Mach F., Koskinas K.C., Roeters van Lennep J.E., et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias // European Heart Journal. — 2025. — Vol. 46. — DOI: 10.1093/eurheartj/ehaf190.

6.Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials // The Lancet. — 2010. — Vol. 376, No. 9753. — P. 1670–1681. — DOI: 10.1016/S0140-6736(10)61350-5.

7.Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease // New England Journal of Medicine. — 2017. — Vol. 376, No. 18. — P. 1713–1722. — DOI: 10.1056/NEJMoa1615664.

8.Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome // New England Journal of Medicine. — 2018. — Vol. 379, No. 22. — P. 2097–2107. — DOI: 10.1056/NEJMoa1801174.

9.Virani S.S., Newby L.K., Arnold S.V., et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease // Circulation. — 2023. — Vol. 148, No. 9. — P. e9–e119. — DOI: 10.1161/CIR.0000000000001168.

10.Vrints C., Andreotti F., Koskinas K.C., et al. 2024 ESC Guidelines for the management of chronic coronary syndromes // European Heart Journal. — 2024. — Vol. 45. — P. 3415–3537.

Downloads

Published

2026-09-22